Do analysts prefer VOR or ZSQR?

Vor Biopharma presently has a consensus target price of $42.25, suggesting a potential upside of 119.37%. Given Vor Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Vor Biopharma is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, VOR or ZSQR?

Vor Biopharma has higher earnings, but lower revenue than Coeptis Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Coeptis Therapeutics $1.36M 198.91 -$11.92M -$2.52 N/A

Does the media favor VOR or ZSQR?

In the previous week, Vor Biopharma and Vor Biopharma both had 3 articles in the media. Vor Biopharma's average media sentiment score of 1.10 beat Coeptis Therapeutics' score of 0.30 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ZSQR or ALVO?

Alvotech has a consensus target price of $7.60, suggesting a potential upside of 148.37%. Given Alvotech's stronger consensus rating and higher probable upside, analysts plainly believe Alvotech is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alvotech 2 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to ZSQR or ALVO?

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 3 articles in the media. Alvotech's average media sentiment score of 0.89 beat Coeptis Therapeutics' score of 0.30 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CVAC or ZSQR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ZSQR or CRON?

Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 18.15%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts clearly believe Cronos Group is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cronos Group 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media refer more to ZSQR or CRON?

In the previous week, Cronos Group had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 6 mentions for Cronos Group and 3 mentions for Coeptis Therapeutics. Cronos Group's average media sentiment score of 0.76 beat Coeptis Therapeutics' score of 0.30 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PURR or ZSQR?

In the previous week, Hyperliquid Strategies had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 3 mentions for Coeptis Therapeutics. Hyperliquid Strategies' average media sentiment score of 1.75 beat Coeptis Therapeutics' score of 0.30 indicating that Hyperliquid Strategies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Coeptis Therapeutics (ZSQR) Competitors

$5.26 +0.50 (+10.50%)

As of 07/24/2026 04:00 PM Eastern

Compare

ZSQR vs. VOR, ALVO, CVAC, CRON, and PURR

Should you buy Coeptis Therapeutics stock or one of its competitors? MarketBeat compares Coeptis Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coeptis Therapeutics include Vor Biopharma (VOR), Alvotech (ALVO), CureVac (CVAC), Cronos Group (CRON), and Hyperliquid Strategies (PURR). These companies are all part of the "pharmaceutical products" industry.

How does Coeptis Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Vor Biopharma has higher earnings, but lower revenue than Coeptis Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Coeptis Therapeutics	$1.36M	198.91	-$11.92M	-$2.52	N/A

Vor Biopharma presently has a consensus target price of $42.25, suggesting a potential upside of 119.37%. Given Vor Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Vor Biopharma is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Vor Biopharma and Vor Biopharma both had 3 articles in the media. Vor Biopharma's average media sentiment score of 1.10 beat Coeptis Therapeutics' score of 0.30 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vor Biopharma has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Vor Biopharma has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Vor Biopharma's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Summary

Vor Biopharma beats Coeptis Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Alvotech?

Coeptis Therapeutics (NASDAQ:ZSQR) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 0.5% of Alvotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 3 articles in the media. Alvotech's average media sentiment score of 0.89 beat Coeptis Therapeutics' score of 0.30 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech has a consensus target price of $7.60, suggesting a potential upside of 148.37%. Given Alvotech's stronger consensus rating and higher probable upside, analysts plainly believe Alvotech is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Coeptis Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Alvotech has higher revenue and earnings than Coeptis Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	198.91	-$11.92M	-$2.52	N/A
Alvotech	$588.90M	1.57	$27.92M	-$0.25	N/A

Alvotech has a net margin of -14.36% compared to Coeptis Therapeutics' net margin of -810.04%. Alvotech's return on equity of -11.92% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Alvotech	-14.36%	-11.92%	-7.59%

Summary

Alvotech beats Coeptis Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

In the previous week, Coeptis Therapeutics had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 0 mentions for CureVac. Coeptis Therapeutics' average media sentiment score of 0.30 beat CureVac's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Coeptis Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CureVac has a net margin of 199.92% compared to Coeptis Therapeutics' net margin of -810.04%. CureVac's return on equity of -23.03% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

CureVac has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Coeptis Therapeutics	$1.36M	198.91	-$11.92M	-$2.52	N/A

17.3% of CureVac shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CureVac beats Coeptis Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Cronos Group?

Coeptis Therapeutics (NASDAQ:ZSQR) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Cronos Group had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 6 mentions for Cronos Group and 3 mentions for Coeptis Therapeutics. Cronos Group's average media sentiment score of 0.76 beat Coeptis Therapeutics' score of 0.30 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cronos Group	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 18.15%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts clearly believe Cronos Group is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Cronos Group has a net margin of -1.14% compared to Coeptis Therapeutics' net margin of -810.04%. Cronos Group's return on equity of -1.26% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Cronos Group	-1.14%	-1.26%	-1.20%

Coeptis Therapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Cronos Group has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	198.91	-$11.92M	-$2.52	N/A
Cronos Group	$146.59M	7.15	-$9.45M	$0.01	281.00

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cronos Group beats Coeptis Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

In the previous week, Hyperliquid Strategies had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 3 mentions for Coeptis Therapeutics. Hyperliquid Strategies' average media sentiment score of 1.75 beat Coeptis Therapeutics' score of 0.30 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperliquid Strategies has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

Hyperliquid Strategies presently has a consensus target price of $12.72, indicating a potential upside of 105.44%. Given Hyperliquid Strategies' stronger consensus rating and higher possible upside, equities analysts plainly believe Hyperliquid Strategies is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Coeptis Therapeutics has higher revenue and earnings than Hyperliquid Strategies. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	894.15	-$16.01M	-$7.37	N/A
Coeptis Therapeutics	$1.36M	198.91	-$11.92M	-$2.52	N/A

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hyperliquid Strategies has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Hyperliquid Strategies' return on equity of -56.04% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Summary

Hyperliquid Strategies beats Coeptis Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZSQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZSQR vs. The Competition

Export

Metric	Coeptis Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$270.53M	$3.67B	$7.06B	$12.20B
Dividend Yield	N/A	2.19%	2.67%	9.41%
P/E Ratio	-2.09	21.29	27.14	23.63
Price / Sales	198.91	297.82	582.30	111.98
Price / Cash	N/A	153.89	49.81	58.78
Price / Book	2.00	7.88	10.28	6.01
Net Income	-$11.92M	$23.86M	$3.60B	$331.99M
7 Day Performance	4.16%	-3.82%	-1.27%	-0.63%
1 Month Performance	-57.78%	-4.45%	-1.67%	-3.04%
1 Year Performance	-54.77%	33.01%	18.25%	13.30%

Coeptis Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZSQR Coeptis Therapeutics	0.1094 of 5 stars	$5.26 +10.5%	N/A	-54.8%	$270.53M	$1.36M	N/A	2	News Coverage Short Interest Increase
VOR Vor Biopharma	2.8227 of 5 stars	$19.51 -2.7%	$42.25 +116.6%	-56.2%	$1.09B	N/A	N/A	140	Positive News
ALVO Alvotech	2.464 of 5 stars	$3.21 -8.9%	$7.60 +137.1%	-68.2%	$1.06B	$588.90M	N/A	1,460	High Trading Volume
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
CRON Cronos Group	1.0877 of 5 stars	$2.78 -0.7%	$2.30 -17.3%	+37.1%	$1.04B	$146.59M	278.28	450	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZSQR) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. VOR, ALVO, CVAC, CRON, and PURR

How does Coeptis Therapeutics compare to Vor Biopharma?

Summary

How does Coeptis Therapeutics compare to Alvotech?

Summary

How does Coeptis Therapeutics compare to CureVac?

Summary

How does Coeptis Therapeutics compare to Cronos Group?

Summary

How does Coeptis Therapeutics compare to Hyperliquid Strategies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. VOR, ALVO, CVAC, CRON, and PURR

How does Coeptis Therapeutics compare to Vor Biopharma?

Which has better earnings and valuation, VOR or ZSQR?

Do analysts prefer VOR or ZSQR?

Does the media favor VOR or ZSQR?

Do insiders and institutionals hold more shares of VOR or ZSQR?

Which has more risk & volatility, VOR or ZSQR?

Is VOR or ZSQR more profitable?

Summary

How does Coeptis Therapeutics compare to Alvotech?

Do insiders & institutionals hold more shares of ZSQR or ALVO?

Does the media refer more to ZSQR or ALVO?

Do analysts rate ZSQR or ALVO?

Which has more volatility & risk, ZSQR or ALVO?

Which has better earnings and valuation, ZSQR or ALVO?

Is ZSQR or ALVO more profitable?

Summary

How does Coeptis Therapeutics compare to CureVac?

Does the media refer more to CVAC or ZSQR?

Do analysts prefer CVAC or ZSQR?

Is CVAC or ZSQR more profitable?

Which has more risk and volatility, CVAC or ZSQR?

Which has preferable earnings and valuation, CVAC or ZSQR?

Do institutionals & insiders hold more shares of CVAC or ZSQR?

Summary

How does Coeptis Therapeutics compare to Cronos Group?

Does the media refer more to ZSQR or CRON?

Do analysts rate ZSQR or CRON?

Is ZSQR or CRON more profitable?

Which has more risk & volatility, ZSQR or CRON?

Which has stronger valuation and earnings, ZSQR or CRON?

Do insiders & institutionals have more ownership in ZSQR or CRON?

Summary

How does Coeptis Therapeutics compare to Hyperliquid Strategies?

Does the media prefer PURR or ZSQR?

Which has more risk & volatility, PURR or ZSQR?

Do analysts prefer PURR or ZSQR?

Which has preferable valuation & earnings, PURR or ZSQR?

Do insiders and institutionals believe in PURR or ZSQR?

Is PURR or ZSQR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools